Kapiva: Building a "Modern Ayurveda" Brand Position in India's Wellness Market

Industry & Competitive Context

India's Ayurveda and herbal wellness category sits within the country's broader AYUSH (Ayurveda, Yoga, Unani, Siddha, Homeopathy) ecosystem, which receives direct government budgetary support — the Ministry of AYUSH was allocated approximately INR 3,712 crore in FY 2024–25 ^[1]. Independent market-research vendors size the category very differently depending on scope (Ayurvedic products vs. broader herbal/alternative-medicine markets), which is itself a useful signal of how fragmented and loosely defined the industry still is: IMARC Group values the India Ayurvedic wellness market at roughly USD 10.3 billion in 2024 ^[2], while a separate Inc42 report citing industry estimates put the broader ayurvedic and herbal wellness market at approximately INR 3.21 lakh crore by 2032, growing at a 17% CAGR ^[3]. These should be read as indicative, vendor-sourced ranges rather than a single authoritative figure. The competitive set spans two distinct generations of players. Legacy, trust-heavy heritage brands — Dabur, Himalaya Wellness, Patanjali Ayurved, and Baidyanath (notable here because Kapiva's founder descends from the Baidyanath family) — dominate mass retail and carry inherited credibility but are also associated with traditional, clinical, or "elderly" brand imagery ^[1][4]. A newer cohort of digital-first, direct-to-consumer (D2C) entrants — including OZiva, Wellbeing Nutrition, Dr. Vaidya's, Cureveda, Gynoveda, and Innovacare — compete for the same urban, digitally native consumer that Kapiva targets, using comparable playbooks of influencer marketing, ecommerce-led distribution, and modern packaging. Trade press covering Kapiva's 2024 funding activity explicitly frames this as a period of intensifying competition among "new age" D2C wellness brands.

Brand Situation Prior to Campaign

Kapiva was founded in 2016 by Ameve Sharma and Shrey Badhani. Sharma is described in company and press materials as a third-generation entrepreneur connected to the Baidyanath Group, a long-established traditional Ayurvedic company. According to a 2021 design-trade profile, Kapiva began as a chain of physical Ayurveda clinics before pivoting by 2018 into Ayurveda-based functional foods and supplements sold through digital channels; at that point the company was reported to be operating at an annualised run-rate of approximately INR 90 crore, with the majority of sales coming through its own D2C website and online marketplaces.

That same profile documents an early visual-identity decision that is central to the brand's positioning: Kapiva's packaging and logo — a blocky "K" monogram, a hand illustration tied to the claim "Sourcing without shortcuts," and an arrow device linking product names to consumer benefits — deliberately departed from the visual conventions of traditional Ayurveda brands (the profile specifically notes the absence of the mortar-and-pestle imagery common to the category).

Strategic Objective

Across multiple founder statements issued through official channels, Kapiva's stated objective is consistent: to make Ayurveda accessible and relevant to time-poor, urban millennial consumers without diluting perceived authenticity. Co-founder Shrey Badhani framed this explicitly at the launch of the brand's 2021 digital campaign: "to reinstate the significance of Ayurveda in our daily lives and create awareness among modern India on how it can be incorporated into fast-paced lives without drastic changes" ^[10]. Founder Ameve Sharma reiterated a trust-and-evidence objective at the time of the company's 2025 Series D round: "We set out to build consumer trust with evidence, and not just claims… This funding represents confidence in our vision to make Ayurveda the preferred choice for holistic wellness". In a separate interview, Sharma stated that the brand prioritises consumer education on Ayurvedic working principles and ingredient benefits as a deliberate marketing investment.

Campaign Architecture & Execution

#StrengthenFromWithin (2021). Kapiva launched a digital campaign onboarding celebrity nutritionist Pooja Makhija alongside more than 30 millennial influencers, centred on everyday Ayurvedic juices. Agency Enormous Brands (Ashish Khazanchi, Founder and Managing Partner) stated the campaign was designed to "introduce the brand to users as modern Ayurveda, for the modern Indian," using "snackable and engaging content" across digital media ^[10][13]. The campaign was reported to have generated over 20 million impressions.

Malaika Arora as strategic investor and brand ambassador (October 2021). Bollywood actor Malaika Arora took a strategic equity stake in Kapiva and was announced as brand ambassador and "wellness mentor" at the company's in-house Kapiva Academy of Ayurveda, described in the announcement as a panel of doctors, nutritionists, food technologists, and innovators that Kapiva says formulates and validates its products ^[14]. At the time of this announcement, Kapiva stated it had a gross merchandise value of more than INR 100 crore and had raised over INR 110 crore from investors including Vertex Ventures, Fireside Ventures, and 3one4 Capital ^[14].

Tiger Shroff as brand ambassador (December 2023). Kapiva announced a partnership with actor Tiger Shroff centred on its Shilajit Gold sports-nutrition product, under the category framing "Ayurveda for Gym, Immunity and Wellness." The official release stated the partnership aimed to "challenge misconceptions surrounding Shilajit" and "reshape perceptions of Ayurveda by spotlighting Shilajit's versatile applications in muscle building, faster recovery, improved energy levels, better metabolism, and enhanced joint health" ^[15][16]. Co-founder Shantanu (as quoted in the release) and the company separately stated that an accompanying ad film "tackles the common trend of people opting for steroids to build muscles," positioning Shilajit Gold as a natural, clinically tested alternative to that shortcut ^[16][17]. The company also stated it had taken two years to scale Shilajit Gold into what it described as the largest and highest-rated natural gym supplement in India, a company claim made via its official LinkedIn channel rather than an independently verified ranking ^[18].

No verified public information is available on the specific media spend, agency roster (beyond Enormous Brands for the 2021 campaign), or contractual terms of the Tiger Shroff or Malaika Arora partnerships.

Positioning & Consumer Insight

The throughline across Kapiva's public statements is a positioning built on two paired tensions: tradition versus modernity, and complexity versus accessibility. Badhani's 2021 statement diagnoses the consumer problem directly — that ancestral, everyday integration of Ayurveda into Indian life had been "lost" over time — and frames Kapiva's product format (juices, gummies, capsules) as the resolution, making Ayurveda fit "fast-paced lives without drastic changes" ^[10]. The packaging strategy documented by trade press reinforces this at a visual level, deliberately avoiding the iconography long associated with Ayurveda as a slow, clinical, or elderly-coded category ^[9]. For the Shilajit Gold/Tiger Shroff execution, the underlying consumer insight — as stated in the official release — was that gym-going consumers commonly default to synthetic, shortcut-oriented muscle-building methods (explicitly referenced as steroids in company materials), and that an Ayurvedic ingredient like Shilajit was misunderstood or stigmatised among this audience ^[16][17]. The campaign's resolution strategy was credibility transfer: pairing a fitness-icon ambassador with stated clinical testing claims to reposition a traditional ingredient as a legitimate, modern performance product. Founder statements at the time of the 2025 funding round reference clinical trial results for two specific products — the Dia Free Juice (blood sugar) and Shilajit Gold (sports nutrition) — as evidence underpinning the brand's "trust with evidence" claim, though the release does not disclose the trials' methodology, sample size, or publication venue.

Media & Channel Strategy

Kapiva's own disclosures describe an omnichannel model rather than a pure-D2C one. As of its September 2025 funding announcement, the company stated it was distributed across approximately 40,000 offline retail stores in India spanning general trade, modern trade, and pharmacy channels, in addition to its own website and ecommerce marketplace presence ^[11][19]. The company has also established wholly owned subsidiaries in the UK, US, and UAE, with international markets contributing an estimated 5–10% of revenue as stated by founder Ameve Sharma ^[19]. The 2021 #StrengthenFromWithin campaign was executed purely through digital and influencer channels ^[10][13], while the 2023 Tiger Shroff partnership was anchored by a produced ad film distributed via the brand's digital and social channels, with Shroff also featured in associated social content ^[16][20]. No verified public information is available on television, out-of-home, or other offline media spend associated with these campaigns.

Business & Brand Outcomes

Funding. Kapiva has raised approximately $90 million in total funding since inception, according to company and investor disclosures around its September 2025 round ^[19][21]. Its Series D round totalled over $60 million, co-led by 360 ONE Asset and Vertex Growth, comprising $28 million in primary capital and $32 million in secondary share sales (the latter providing an exit to early backer Fireside Ventures); the round had been opened in September 2024 with a $10 million tranche from OrbiMed Asia, Vertex Ventures, and 3one4 Capital ^[19][21]. An earlier, separate Tracxn data aggregation cites total funding of $78.5 million from investors including OrbiMed, Jetty Ventures, and Fireside Ventures, a figure that does not fully reconcile with the press-reported ~$90 million and is presented here for completeness rather than as a reconciled total ^[22].

Revenue and profitability. Per Inc42's reporting (sourced to company financial filings), Kapiva's total revenue including interest income was approximately INR 116.5 crore in FY23, up from INR 62.4 crore in FY22; standalone FY24 revenue was reported at INR 229 crore ^[6]. The company's loss widened 34% to INR 64.6 crore in FY23 from INR 48.2 crore in FY22 ^[6]. A separate Indiatimes report cited by Tracxn states FY23 revenue "doubled" to INR 114 crore ^[22] — a figure close to but not identical to Inc42's INR 116.5 crore, likely reflecting different revenue-line definitions across the two reports. As of its September 2025 funding round, Kapiva stated an annual revenue run rate (ARR) of approximately INR 550 crore, having grown over 80% year-on-year over the preceding three years according to the company ^[19][21]; the same release states the company employed over 500 people at that time ^[21].

Campaign-level metrics. The only publicly disclosed campaign-specific performance figure identified is the 20-million-plus impressions reported for the 2021 #StrengthenFromWithin campaign ^[10]. No verified public information is available on sales conversion, customer acquisition cost, retention, repeat-purchase rate, or revenue attribution for the Malaika Arora or Tiger Shroff brand-ambassador partnerships, nor for the 2024–25 "brand building at scale" marketing investment referenced in the Series D release. Some secondary aggregator and SEO-content websites circulate specific uplift figures (e.g., impression counts and percentage sales or search-interest increases) attributed to later Kapiva campaigns; these claims could not be traced to an original company disclosure, investor filing, or credible news outlet and have therefore been excluded from this case in line with verification standards.

Strategic Implications

Kapiva's brand architecture illustrates a sequencing strategy for building credibility in a low-trust, high-skepticism category. The company moved from an expert-credibility play (nutritionist Pooja Makhija, 2021) to an equity-aligned celebrity endorsement bundled with an internal scientific advisory body (Malaika Arora and the Kapiva Academy of Ayurveda, 2021) to a category-specific male fitness-icon partnership targeting a previously underpenetrated gym/sports-nutrition audience (Tiger Shroff, 2023). Read together, this is a portfolio approach to trust-building rather than a single campaign: each partnership targets a different consumer segment and a different source of skepticism — clinical credibility, family/lifestyle aspiration, and athletic-performance proof, respectively. The repeated emphasis on "evidence, not just claims" and on an in-house "Academy" also reflects a structural response to a category-wide problem: Ayurveda as a category lacks the regulatory and clinical-trial infrastructure of pharmaceuticals, making third-party credibility (doctors, nutritionists, clinical-trial references) a substitute for regulatory proof points. Institutionalising this in-house, rather than relying solely on external endorsement, is a defensible long-term brand-equity move, though the absence of public detail on the referenced clinical trials limits independent verification of these claims. Financially, Kapiva's own framing of its Series D proceeds — explicitly earmarked for "brand building at scale" alongside R&D and manufacturing ^[19][21] — signals that the company itself treats brand investment as a primary lever for category leadership, ahead of pure distribution or pricing competition. Its parallel investment in 40,000-store offline distribution alongside D2C and marketplace channels also suggests a hedge against the well-documented escalation in digital customer-acquisition costs across India's broader D2C sector, a dynamic referenced contextually in trade coverage of the competitive landscape ^[6], though no Kapiva-specific acquisition-cost data is publicly available to confirm this as a stated rationale.

Discussion Questions

1. Kapiva sequenced its ambassador strategy from a credentialed nutritionist to a celebrity-investor to a category-specific fitness icon. What are the risks and benefits of using multiple, segment-specific ambassadors over time versus a single, consistent brand face?

   
   

2. The case shows meaningful discrepancies between different public sources on Kapiva's total funding (~$78.5M vs. ~$90M) and FY23 revenue (INR 114 Cr vs. INR 116.5 Cr). How should an analyst handle conflicting figures from credible but non-identical sources when building a company assessment?

   
   

3. Kapiva created an in-house "Academy of Ayurveda" to formulate and validate products. Evaluate this as a substitute for third-party regulatory or clinical credibility in a category (Ayurveda) with limited standardized scientific validation infrastructure.

   
   

4. Kapiva's 2023 Shilajit Gold campaign directly confronted a competing consumer behavior (steroid use) rather than a competing brand. What are the strategic advantages and risks of positioning against a behavior instead of a named competitor?

   
   

5. Given that Kapiva's own disclosures emphasize omnichannel distribution (40,000 offline stores) alongside D2C, what does this suggest about the limits of a pure digital-first growth model in a category where consumer trust is a primary purchase barrier?